Marea Ther­a­peu­tics launch­es with $190M, see­ing a 'fix­able prob­lem' in a ne­glect­ed car­diometa­bol­ic tar­get

A Third Rock Ven­tures-in­cu­bat­ed start­up called Marea Ther­a­peu­tics de­buted Tues­day with $190 mil­lion to ad­vance a drug for a ge­net­ic tar­get for car­diometa­bol­ic dis­eases. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER